1. AMVUTTRA
Amvuttra is a brand drug owned by Alnylam Pharmaceuticals Inc. It is Used for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It was approved for market use on Jun 13, 2022. Amvuttra uses Vutrisiran Sodium as an active ingredient.
Total Patents:
13
Expired Patents:
0
Amvuttra's NCE-1 date is Jun 13, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Amvuttra
2. BAXDELA
Baxdela is a brand drug owned by Melinta Subsidiary Corp. It is used for treating acute bacterial skin infections in adults. It was approved for market use on Jun 19, 2017. Baxdela uses Delafloxacin Meglumine as an active ingredient.
Total Patents:
16
Expired Patents:
3
Baxdela's NCE-1 date is Jun 19, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Baxdela
3. BLUDIGO
Bludigo is a brand drug owned by Provepharm Sas. It was approved for market use on Jul 8, 2022. Bludigo uses Indigotindisulfonate Sodium as an active ingredient.
Total Patents:
3
Expired Patents:
0
Bludigo's NCE-1 date is Jul 08, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Bludigo
4. BOSULIF
Bosulif is a brand drug owned by Pf Prism Cv. It is used for treating BCR-ABL positive leukemia resistant to imatinib, including patients with specific BCR-ABL mutations and various phases of CML. It was approved for market use on Sep 4, 2012. Bosulif uses Bosutinib Monohydrate as an active ingredient.
Total Patents:
11
Expired Patents:
5
Bosulif's NCE-1 date is Mar 26, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Bosulif
5. CAMZYOS
Camzyos is a brand drug owned by Bristol Myers Squibb Co. It is Used for improving functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in NYHA class II-III. It was approved for market use on Apr 28, 2022. Camzyos uses Mavacamten as an active ingredient.
Total Patents:
3
Expired Patents:
0
Camzyos's NCE-1 date is Apr 28, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Camzyos
6. CIBINQO
Cibinqo is a brand drug owned by Pfizer Inc. It is Used for treating adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products. It was approved for market use on Jan 14, 2022. Cibinqo uses Abrocitinib as an active ingredient.
Total Patents:
3
Expired Patents:
0
Cibinqo's NCE-1 date is Jan 14, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Cibinqo
7. EDURANT
Edurant is a brand drug owned by Janssen Products Lp. It is Used for treating HIV-1 infection in treatment-naive adult patients with low viral load. It was approved for market use on May 20, 2011. Edurant uses Rilpivirine Hydrochloride as an active ingredient.
Total Patents:
7
Expired Patents:
7
Edurant's NCE-1 date is Sep 15, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Edurant
8. ELUCIREM
Elucirem is a brand drug owned by Guerbet. It was approved for market use on Sep 21, 2022. Elucirem uses Gadopiclenol as an active ingredient.
Total Patents:
3
Expired Patents:
0
Elucirem's NCE-1 date is Sep 21, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Elucirem
9. EPCLUSA
Epclusa is a brand drug owned by Gilead Sciences Inc. It is Used for treating hepatitis C. It was approved for market use on Mar 19, 2020. Epclusa uses Sofosbuvir; Velpatasvir as an active ingredient.
Total Patents:
30
Expired Patents:
0
Epclusa's NCE-1 date is Sep 19, 2026 which is when its patents will be open to challenges.
Check the entire list of patents and their expiration dates for Epclusa